Ryverna Solution for Infusion

Ryverna Solution for Infusion belongs to the group of medicines called monoclonal antibodies, which is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. A vaso-occlusive crisis, or VOC, occurs when sickled red blood cells obstruct blood flow to the point where tissues are deprived of oxygen. This, in turn, causes an inflammatory reaction. The outcome is severe pain, which can affect any part of the body but is most typically felt in the back, chest, or extremities.

Ryverna Solution for Infusion contains Crizanlizumab-tmca, which works by blocking certain blood cells from interacting.

Ryverna Solution for Infusion will be administered by a healthcare professional; do not self-administer. Your doctor will decide the dose and duration based on your medical condition. In some cases, Ryverna Solution for Infusion may cause Infusion site reactions, nausea, arthralgia (pain in a joint), back pain, and pyrexia (fever). Most of these side effects do not require medical treatment and fade away with time. However, consult your doctor if the side effects persist or worsen.

Before taking the Ryverna Solution for Infusion, let your doctor know about all your medical conditions, sensitivities, and medications you are using. Ryverna Solution for Infusion may cause fetal harm. So, inform your doctor if you are pregnant and planning to become pregnant. Do not breastfeed while on medication unless recommended by the doctor. Ryverna Solution for Infusion is not recommended for children below 16 years as the safety and effectiveness have not been established. Consumption of alcohol is not recommended while on therapy.

Ryverna Solution for Infusion contains Crizanlizumab-tmca, which belongs to the group of medicines called monoclonal antibodies and is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. Crizanlizumab-tmca which works by binding to the protein P-selectin in the blood. This protein is responsible for the adhesion of blood cells. By inhibiting P-selectin, blood cell limitations are avoided, and blood supply throughout the body is improved.

Before using the Ryverna Solution for Infusion, inform your doctor about your medical conditions (e.g., pregnancy, nursing, any scheduled surgery, etc.), sensitivities (allergic reactions to foods and medicines), and medications you are taking. Other drugs (especially corticosteroids) or supplements should not be taken with Ryverna Solution for Infusion unless prescribed by a doctor. Do not miss any doses and finish the entire course of medicine. Stopping the drug too soon may cause the infection to reoccur or worsen.

• Platelet Counts should be evaluated on a regular basis throughout Ryverna Solution for Infusion treatment and until full recovery is achieved.